Literature DB >> 29316341

Benefits and Sustainability of a Learning Collaborative for Implementation of Treat-to-Target in Rheumatoid Arthritis: Results of a Cluster-Randomized Controlled Phase II Clinical Trial.

Daniel H Solomon1, Bing Lu1, Zhi Yu1, Cassandra Corrigan1, Leslie R Harrold2, Josef S Smolen3, Liana Fraenkel4, Jeffrey N Katz1, Elena Losina1.   

Abstract

OBJECTIVE: We conducted a 2-phase randomized controlled trial of a learning collaborative to facilitate implementation of treat-to-target (T2T) to manage rheumatoid arthritis (RA). We found substantial improvement in implementation of T2T in phase I. Here, we report on a second 9 months (phase II), where we examined the maintenance of response in phase I and predictors of greater improvement in T2T adherence.
METHODS: We recruited patients from 11 rheumatology sites and randomized them to either receive the learning collaborative during phase I or to a wait-list control group that received the learning collaborative intervention during phase II. The outcome was change in T2T implementation score (0-100, where 100 = best) from pre- to postintervention. The T2T implementation score was defined as a percent of components documented in visit notes. Analyses examined the extent to which the phase-I intervention teams sustained improvement in T2T, as well as predictors of T2T improvement.
RESULTS: The analysis included 636 RA patients. At baseline, the mean T2T implementation score was 11% in phase I intervention sites and 13% in phase II sites. After the intervention, T2T implementation score improved to 57% in the phase I intervention sites and to 58% in the phase II sites. Intervention sites from phase I sustained the improvement during the phase II (52%). Predictors of greater T2T improvement included having only rheumatologist providers at the site, academic affiliation of the site, having fewer providers per site, and the rheumatologist provider being a trainee.
CONCLUSION: Improvement in T2T remained relatively stable over a postintervention period.
© 2018, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29316341      PMCID: PMC6033691          DOI: 10.1002/acr.23508

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  14 in total

1.  Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations.

Authors:  Leslie R Harrold; J Timothy Harrington; Jeffrey R Curtis; Daniel E Furst; Mary Jane Bentley; Ying Shan; George Reed; Joel Kremer; Jeffrey D Greenberg
Journal:  Arthritis Rheum       Date:  2012-03

2.  Implementation of treat-to-target in rheumatoid arthritis through a Learning Collaborative: Rationale and design of the TRACTION trial.

Authors:  Daniel H Solomon; Sara B Lee; Agnes Zak; Cassandra Corrigan; Jenifer Agosti; Asaf Bitton; Leslie Harrold; Elena Losina; Bing Lu; Ted Pincus; Helga Radner; Josef Smolen; Jeffrey N Katz; Liana Fraenkel
Journal:  Semin Arthritis Rheum       Date:  2016-03-08       Impact factor: 5.532

Review 3.  Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.

Authors:  Jaclyn Anderson; Liron Caplan; Jinoos Yazdany; Mark L Robbins; Tuhina Neogi; Kaleb Michaud; Kenneth G Saag; James R O'Dell; Salahuddin Kazi
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

Review 4.  2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Authors:  Jasvinder A Singh; Daniel E Furst; Aseem Bharat; Jeffrey R Curtis; Arthur F Kavanaugh; Joel M Kremer; Larry W Moreland; James O'Dell; Kevin L Winthrop; Timothy Beukelman; S Louis Bridges; W Winn Chatham; Harold E Paulus; Maria Suarez-Almazor; Claire Bombardier; Maxime Dougados; Dinesh Khanna; Charles M King; Amye L Leong; Eric L Matteson; John T Schousboe; Eileen Moynihan; Karen S Kolba; Archana Jain; Elizabeth R Volkmann; Harsh Agrawal; Sangmee Bae; Amy S Mudano; Nivedita M Patkar; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

5.  Impact of a quality improvement program on care and outcomes for children with asthma.

Authors:  Charles J Homer; Peter Forbes; Lisa Horvitz; Laura E Peterson; David Wypij; Patricia Heinrich
Journal:  Arch Pediatr Adolesc Med       Date:  2005-05

6.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

Authors:  Catriona Grigor; Hilary Capell; Anne Stirling; Alex D McMahon; Peter Lock; Ramsay Vallance; Wilma Kincaid; Duncan Porter
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

7.  Effects of a quality improvement collaborative on the outcome of care of patients with HIV infection: the EQHIV study.

Authors:  Bruce E Landon; Ira B Wilson; Keith McInnes; Mary Beth Landrum; Lisa Hirschhorn; Peter V Marsden; David Gustafson; Paul D Cleary
Journal:  Ann Intern Med       Date:  2004-06-01       Impact factor: 25.391

8.  Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity.

Authors:  Kathleen Tymms; Jane Zochling; James Scott; Paul Bird; Simon Burnet; Julien de Jager; Hedley Griffiths; Dave Nicholls; Lynden Roberts; Mark Arnold; Geoffrey Littlejohn
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-02       Impact factor: 4.794

9.  Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial).

Authors:  S M M Verstappen; J W G Jacobs; M J van der Veen; A H M Heurkens; Y Schenk; E J ter Borg; A A M Blaauw; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-05-22       Impact factor: 19.103

10.  Treating rheumatoid arthritis to target: recommendations of an international task force.

Authors:  Josef S Smolen; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maarten de Wit; Maxime Dougados; Paul Emery; Alan Gibofsky; Juan Jesus Gomez-Reino; Boulos Haraoui; Joachim Kalden; Edward C Keystone; Tore K Kvien; Iain McInnes; Emilio Martin-Mola; Carlomaurizio Montecucco; Monika Schoels; Désirée van der Heijde; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-03-09       Impact factor: 19.103

View more
  6 in total

1.  Treat-to-target concept implementation for evaluating rheumatoid arthritis patients in daily practice.

Authors:  Tal Gazitt; Shirley Oren; Tatiana Reitblat; Merav Lidar; Alexandra Balbir Gurman; Itzhak Rosner; Nimer Halabe; Joy Feld; Sameer Kassem; Idit Lavi; Ori Elkayam; Devy Zisman
Journal:  Eur J Rheumatol       Date:  2019-05-20

Review 2.  Potential Future Directions in Optimization of Students' Performance Prediction System.

Authors:  Sadique Ahmad; Mohammed A El-Affendi; M Shahid Anwar; Rizwan Iqbal
Journal:  Comput Intell Neurosci       Date:  2022-05-17

3.  Adverse Events and Resource Use Before and After Treat-to-Target in Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial.

Authors:  Daniel H Solomon; Zhi Yu; Jeffrey N Katz; Asaf Bitton; Cassandra Corrigan; Liana Fraenkel; Leslie R Harrold; Josef S Smolen; Elena Losina; Bing Lu
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-07-19       Impact factor: 4.794

Review 4.  Treat-to-target in PsA: methods and necessity.

Authors:  Emma Dures; Sasha Shepperd; Sandeep Mukherjee; Jo Robson; Ivo Vlaev; Nicola Walsh; Laura C Coates
Journal:  RMD Open       Date:  2020-02

5.  The DNA co-vaccination using Sm antigen and IL-10 as prophylactic experimental therapy ameliorates nephritis in a model of lupus induced by pristane.

Authors:  Beatriz Teresita Martín-Márquez; Minoru Satoh; Rogelio Hernández-Pando; Erika Aurora Martínez-García; Marcelo Heron Petri; Flavio Sandoval-García; Oscar Pizano-Martinez; Trinidad García-Iglesias; Fernanda Isadora Corona-Meraz; Monica Vázquez-Del Mercado
Journal:  PLoS One       Date:  2021-10-27       Impact factor: 3.240

6.  Implementing a Treat-to-Target Approach for Rheumatoid Arthritis During the COVID-19 Pandemic: Results of a Virtual Learning Collaborative Program.

Authors:  Daniel H Solomon; Theodore Pincus; Nancy A Shadick; Jacklyn Stratton; Jack Ellrodt; Leah Santacroce; Jeffrey N Katz; Josef S Smolen
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-02-04       Impact factor: 5.178

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.